Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signals

Clinical Immunology

Volumn 135, Issue 2, 2010, Pages 210-222

  Henderson, Cailin ^a   Goldbach Mansky, Raphaela ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Anakinra; Autoinflammatory diseases; DIRA; Genetic disease; IL 1; IL 1Ra; IL1RN; Neonatal disorder; NLRP3; NOD like receptors; NOMID CINCA

Indexed keywords

ALPHA INTERFERON; AZITHROMYCIN; CANAKINUMAB; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; METHOTREXATE; MYELOID DIFFERENTIATION FACTOR 88; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOLL LIKE RECEPTOR;

ALZHEIMER DISEASE; ANTIGEN RECOGNITION; ASBESTOSIS; AUTOINFLAMMATORY DISEASE; BONE MARROW TRANSPLANTATION; CINCA SYNDROME; CLINICAL FEATURE; CYTOKINE RELEASE; DIABETES MELLITUS; DNA MODIFICATION; DOWN REGULATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GENE MUTATION; GENE TARGETING; GENETIC DISORDER; GOUT; HUMAN; IMMUNE DEFICIENCY; IMMUNOREGULATION; INFECTION RISK; INNATE IMMUNITY; MONOGENIC DISORDER; MUCKLE WELLS SYNDROME; NEWBORN DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SILICOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

AUTOIMMUNE DISEASES; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFLAMMATION; INTERLEUKIN-1; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 77950630298     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.02.013     Document Type: Review

References (103)

1. Medzhitov R. Origin and physiological roles of inflammation. Nature 454 7203 (2008) 428-435
2. Medzhitov R., and Janeway Jr. C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91 3 (1997) 295-298
3. O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226 (2008) 10-18
4. Jha S., and Ting J.P. Inflammasome-associated nucleotide-binding domain, leucine-rich repeat proteins and inflammatory diseases. J. Immunol. 183 12 (2009) 7623-7629
5. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27 (2009) 519-550
6. Balavoine J.F., et al. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78 4 (1986) 1120-1124
7. Hannum C.H., et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343 6256 (1990) 336-340
8. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 6 (1996) 2095-2147
9. http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/anakamg062703LB.pdf.
10. Voronov E., et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 100 5 (2003) 2645-2650
11. Keller M., et al. Active caspase-1 is a regulator of unconventional protein secretion. Cell 132 5 (2008) 818-831
12. Kaspar R.L., and Gehrke L. Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1 beta mRNA show unequal IL-1 beta protein accumulation but similar polyribosome profiles. J. Immunol. 153 1 (1994) 277-286
13. Dinarello C.A., et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J. Immunol. 139 6 (1987) 1902-1910
14. Greten F.R., et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130 5 (2007) 918-931
15. Schindler R., Ghezzi P., and Dinarello C.A. IL-1 induces IL-1. IV. IFN-gamma suppresses IL-1 but not lipopolysaccharide-induced transcription of IL-1. J. Immunol. 144 6 (1990) 2216-2222
16. Mariathasan S., et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 7081 (2006) 228-232
17. Kahlenberg J.M., and Dubyak G.R. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am. J. Physiol. Cell Physiol. 286 5 (2004) C1100-C1108
18. Kagan J.C., et al. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat. Immunol. 9 4 (2008) 361-368
19. Martinon F., Burns K., and Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10 2 (2002) 417-426
20. Sutterwala F.S., et al. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24 3 (2006) 317-327
21. Mariathasan S., et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430 6996 (2004) 213-218
22. Li P., et al. Characterization of mice deficient in interleukin-1 beta converting enzyme. J. Cell. Biochem. 64 1 (1997) 27-32
23. Kanneganti T.D., et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281 48 (2006) 36560-36568
24. Kanneganti T.D., et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440 7081 (2006) 233-236
25. Martinon F., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440 7081 (2006) 237-241
26. Di Paolo N.C., et al. Virus binding to a plasma membrane receptor triggers interleukin-1 alpha-mediated proinflammatory macrophage response in vivo. Immunity 31 1 (2009) 110-121
27. Muruve D.A., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452 7183 (2008) 103-107
28. Marina-Garcia N., et al. Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2. J. Immunol. 180 6 (2008) 4050-4057
29. Dostert C., et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 5876 (2008) 674-677
30. Hornung V., et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9 8 (2008) 847-856
31. Cassel S.L., et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc. Natl. Acad. Sci. U. S. A. 105 26 (2008) 9035-9040
32. Li H., et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181 1 (2008) 17-21
33. Eisenbarth S.C., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 7198 (2008) 1122-1126
34. Kool M., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181 6 (2008) 3755-3759
35. Yamasaki K., et al. NLRP3/cryopyrin is necessary for interleukin-1beta (IL-1beta) release in response to hyaluronan, an endogenous trigger of inflammation in response to injury. J. Biol. Chem. 284 19 (2009) 12762-12771
36. Halle A., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 9 8 (2008) 857-865
37. Masters S.L., et al. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu. Rev. Immunol. 27 (2009) 621-668
38. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 90 4 (1997) 797-807
39. A candidate gene for familial Mediterranean fever. Nat Genet 17 1 (1997) 25-31
40. McDermott M.F., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97 1 (1999) 133-144
41. Drenth J.P., et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat. Genet. 22 2 (1999) 178-181
42. Houten S.M., et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat. Genet. 22 2 (1999) 175-177
43. Kanazawa N., et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 105 3 (2005) 1195-1197
44. Miceli-Richard C., et al. CARD15 mutations in Blau syndrome. Nat. Genet. 29 1 (2001) 19-20
45. Wise C.A., et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum. Mol. Genet. 11 8 (2002) 961-969
46. Hoffman H.M., et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29 3 (2001) 301-305
47. Aksentijevich I., et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46 12 (2002) 3340-3348
48. Feldmann J., et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71 1 (2002) 198-203
49. Aksentijevich I., et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360 23 (2009) 2426-2437
50. Reddy S., et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360 23 (2009) 2438-2444
51. Koziczak-Holbro M., et al. IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and Toll-like receptor 7-mediated signaling and gene expression. J. Biol. Chem. 282 18 (2007) 13552-13560
52. Muzio M., et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278 5343 (1997) 1612-1615
53. von Bernuth H., et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321 5889 (2008) 691-696
54. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
55. Picard C., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 5615 (2003) 2076-2079
56. Enders A., et al. Two siblings with lethal pneumococcal meningitis in a family with a mutation in Interleukin-1 receptor-associated kinase 4. J. Pediatr. 145 5 (2004) 698-700
57. Ku C.L., et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J. Exp. Med. 204 10 (2007) 2407-2422
58. Ku C.L., et al. Inherited disorders of human Toll-like receptor signaling: immunological implications. Immunol. Rev. 203 (2005) 10-20
59. Janssen R., et al. Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 50 10 (2004) 3329-3333
60. Muckle T.J. The 'Muckle-Wells' syndrome. Br. J. Dermatol. 100 1 (1979) 87-92
61. Gattorno M., et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58 5 (2008) 1516-1520
62. Goldbach-Mansky R., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355 6 (2006) 581-592
63. Hawkins P.N., et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 50 2 (2004) 607-612
64. Lovell D.J., Bowyer S.L., and Solinger A.M. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 52 4 (2005) 1283-1286
65. Hoffman H.M., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum. 58 8 (2008) 2443-2452
66. Maksimovic L., et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 47 3 (2008) 309-310
67. Lachmann H.J., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360 23 (2009) 2416-2425
68. IL-1beta-targeted antibody approved for rare autoinflammatory disorders. Nat. Rev. Drug Discov. 8 8 (2009) 605
69. Hill S.C., et al. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatr. Radiol. 37 2 (2007) 145-152
70. Kalyoncu M., et al. Are carriers for MEFV mutations "healthy"?. Clin. Exp. Rheumatol. 24 5 Suppl 42 (2006) S120-S122
71. Lachmann H.J., et al. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 45 6 (2006) 746-750
72. Chae J.J., et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc. Natl. Acad. Sci. U. S. A. 103 26 (2006) 9982-9987
73. Papin S., et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing. Cell Death Differ. 14 8 (2007) 1457-1466
74. Yu J.W., et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ. 13 2 (2006) 236-249
75. Belkhir R., et al. Treatment of familial Mediterranean fever with anakinra. Ann. Intern. Med. 146 11 (2007) 825-826
76. Calligaris L., et al. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur. J. Pediatr. 167 6 (2008) 695-696
77. Gattringer R., et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur. J. Clin. Invest. 37 11 (2007) 912-914
78. Kuijk L.M., et al. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann. Rheum. Dis. 66 11 (2007) 1545-1546
79. Roldan R., et al. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 75 4 (2008) 504-505
80. Shoham N.G., et al. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. U. S. A. 100 23 (2003) 13501-13506
81. Yu J.W., et al. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol. Cell 28 2 (2007) 214-227
82. Kuijk L.M., et al. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 112 9 (2008) 3563-3573
83. Bodar E.J., et al. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63 7 (2005) 260-264
84. Cailliez M., et al. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 29 6 (2006) 763
85. McGonagle D., et al. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66 12 (2007) 1683-1684
86. So A., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9 2 (2007) R28
87. Terkeltaub R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68 10 (2009) 1613-1617
88. Larsen C.M., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356 15 (2007) 1517-1526
89. Botsios C., et al. Resistant Behcet disease responsive to anakinra. Ann. Intern. Med. 149 4 (2008) 284-286
90. Sanz J.M., et al. Activation of microglia by amyloid beta requires P2X7 receptor expression. J. Immunol. 182 7 (2009) 4378-4385
91. Ferguson P.J., et al. A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis. Bone 38 1 (2006) 41-47
92. Grosse J., et al. Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease. Blood 107 8 (2006) 3350-3358
93. Lequerre T., et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67 3 (2008) 302-308
94. Goldbach-Mansky R., and Kastner D.L. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J. Allergy Clin. Immunol. 124 6 (2009) 1141-1149 quiz 1150-1
95. Crossman D.C., et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials 9 (2008) 8
96. Glocker E.O., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361 21 (2009) 2033-2045
97. Franke A., et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40 11 (2008) 1319-1323
98. Imielinski M., et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat. Genet. 41 12 (2009) 1335-1340
99. Wallace G.R., et al. IL-10 genotype analysis in patients with Behcet's disease. Hum. Immunol. 68 2 (2007) 122-127
100. Filipe-Santos O., et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18 6 (2006) 347-361
101. Ferwerda B., et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361 18 (2009) 1760-1767
102. Glocker E.O., et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361 18 (2009) 1727-1735
103. Holland S.M., and Vinh D.C. Yeast infections - human genetics on the rise. N. Engl. J. Med. 361 18 (2009) 1798-1801